BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an ...
The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC ...
If the FDA and CDC sit on their hands, next season the flu shot will be a lot more expensive, if you can find it at all. That ...
The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for ...
More states are loosening vaccine mandates, scaling back vaccine promotion efforts and taking other steps likely to lower ...
21h
MedPage Today on MSNMarty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDANow the Johns Hopkins University surgeon and researcher has been nominated to lead the FDA. The agency -- responsible for ...
If passed, anyone who provides or administers a gene-based vaccine to another person would face a penalty of $500 per ...
19hon MSN
Now the Johns Hopkins University surgeon and researcher has been nominated to lead the Food and Drug Administration. The ...
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...
Public health experts say they are on edge about the upcoming influenza vaccine after the Food and Drug Administration canceled a routine advisory meeting last week.
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results